Expert Discusses Home Treatment for Aggressive Lymphomas Amidst COVID-19 Pandemic

Article

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

Transcription:

We’ve also set up to do many of our treatments at home that we used to hospitalize patients for. For example, patients that require infusional chemotherapy, not bolus, like R-EPOCH, we now do it at home. We have all the SOPs working fine and have not had any unforeseen or adverse events occur in the home setting, and patients seem to like it. I think the silver lining in all of this is that as we begin to open up again, we’re probably going to maintain a lot of the procedures that we’ve implemented. For example, in terms of cleaning and trying to stagger patients, I think this has been a learning experience. We’ve done very well without observing any complications. So, I think that we’ll continue to maintain-I mean it’ll just be as important during flu season, etc. to try to stagger visits, do extra cleaning, and then to treat patients at home. The ability to do televisits is very convenient for patients when they don’t actually have to be examined, or they’re not having a problem where it’s a routine follow up, touching bases, review labs, reviewing images with the patients. It’s a great way to do it. Now that we have the technology up and running, I don’t think it’s going to disappear.

Recent Videos
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.